ATE529531T1 - Gm3-synthase als therapeutisches ziel bei mikrovaskulären komplikationen des diabetes - Google Patents

Gm3-synthase als therapeutisches ziel bei mikrovaskulären komplikationen des diabetes

Info

Publication number
ATE529531T1
ATE529531T1 AT05716551T AT05716551T ATE529531T1 AT E529531 T1 ATE529531 T1 AT E529531T1 AT 05716551 T AT05716551 T AT 05716551T AT 05716551 T AT05716551 T AT 05716551T AT E529531 T1 ATE529531 T1 AT E529531T1
Authority
AT
Austria
Prior art keywords
diabetes
synthase
therapeutic target
microvascular complications
complications
Prior art date
Application number
AT05716551T
Other languages
English (en)
Inventor
Samer Elbawab
Elodie Masson
Daniel Ruggiero
Nicolas Wiernsperger
Michel Lagarde
Lysiane Troncy
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0404971A external-priority patent/FR2869915B1/fr
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE529531T1 publication Critical patent/ATE529531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
AT05716551T 2004-05-07 2005-04-07 Gm3-synthase als therapeutisches ziel bei mikrovaskulären komplikationen des diabetes ATE529531T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0404971A FR2869915B1 (fr) 2004-05-07 2004-05-07 Gm3 synthase, comme cible therapeutique dans les complications microvasculaires du diabete
FR0413530 2004-12-17
PCT/EP2005/003647 WO2005108600A1 (en) 2004-05-07 2005-04-07 Gm3 synthase as a therapeutic target in microvascular complications of diabetes

Publications (1)

Publication Number Publication Date
ATE529531T1 true ATE529531T1 (de) 2011-11-15

Family

ID=34979036

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05716551T ATE529531T1 (de) 2004-05-07 2005-04-07 Gm3-synthase als therapeutisches ziel bei mikrovaskulären komplikationen des diabetes

Country Status (12)

Country Link
US (1) US20070224200A1 (de)
EP (1) EP1743033B1 (de)
JP (1) JP4921357B2 (de)
KR (1) KR20070007908A (de)
AT (1) ATE529531T1 (de)
AU (1) AU2005240714B2 (de)
BR (1) BRPI0510697A (de)
CA (1) CA2565676C (de)
ES (1) ES2375626T3 (de)
MX (1) MXPA06012690A (de)
RU (1) RU2006143156A (de)
WO (1) WO2005108600A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161586A1 (en) * 2004-01-16 2007-07-12 Takeda Pharmaceutical Company Limited Drug for preventing and treating atherosclerosis
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
KR100734928B1 (ko) 2006-02-16 2007-07-03 한국생명공학연구원 갱글리오사이드 ＧＭ3 합성효소를 저해하는 ｓｉ핵산 및 그서열
DK2032134T3 (en) 2006-05-09 2015-09-28 Genzyme Corp Processes for the treatment of fatty liver disease which includes inhibition of glucosphingolipidsyntese
US8465930B2 (en) 2006-05-30 2013-06-18 Japan Science And Technology Agency Method for detection of disease having insulin-resistant conditions
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
BRPI0823522A2 (pt) 2007-10-05 2014-01-07 Genzyme Corp Uso de um composto derivado de ceramida
JP2011529500A (ja) 2008-07-28 2011-12-08 ジェンザイム コーポレーション 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8691514B2 (en) 2008-10-31 2014-04-08 Japan Science And Technology Agency Method for selective control of helper T cell function
EP2411526A4 (de) * 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc Modulatoren der gangliosidenbiosynthese
EP2473615B1 (de) 2009-09-01 2016-04-06 LZ Therapeutics, Inc. Herstellung von GM1 durch Zellkulturen (nicht vom Rind oder Schwein)
US9090932B2 (en) * 2009-11-27 2015-07-28 Japan Science And Technology Agency Method for screening of therapeutic agent for hyperlipemia
WO2011133918A1 (en) * 2010-04-23 2011-10-27 Isis Pharmaceuticals, Inc. Modulation of gm3 synthase (gm3s) expression
WO2011146804A2 (en) * 2010-05-20 2011-11-24 Lazarus Therapeutics, Inc. Gm3 ganglioside replacement therapy
US20130040953A1 (en) * 2011-08-10 2013-02-14 Amy S. Paller Promotion of wound healing
US9556467B2 (en) 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production
EP3318277A1 (de) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitoren der glucosylceramidsynthase zur behandlung von motoneuronerkrankungen
WO2019082912A1 (ja) * 2017-10-27 2019-05-02 学校法人北里研究所 慢性腎臓病の予防又は治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5000000A (en) * 1988-08-31 1991-03-19 University Of Florida Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes
US6555371B1 (en) * 1997-07-09 2003-04-29 Seikagaku Kogyo Kabushiki Kaisha Sialyltransferase and DNA encoding the same
US6280989B1 (en) * 1999-06-17 2001-08-28 Dmitri Kapitonov Sialyltransferases
EP1633770B1 (de) * 2003-06-13 2015-04-29 Alnylam Europe AG Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus

Also Published As

Publication number Publication date
KR20070007908A (ko) 2007-01-16
WO2005108600A1 (en) 2005-11-17
EP1743033B1 (de) 2011-10-19
AU2005240714B2 (en) 2011-07-07
EP1743033A1 (de) 2007-01-17
JP4921357B2 (ja) 2012-04-25
US20070224200A1 (en) 2007-09-27
MXPA06012690A (es) 2007-01-16
RU2006143156A (ru) 2008-06-20
ES2375626T3 (es) 2012-03-02
BRPI0510697A (pt) 2007-12-26
CA2565676A1 (en) 2005-11-17
JP2007536292A (ja) 2007-12-13
CA2565676C (en) 2013-08-13
AU2005240714A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
ATE529531T1 (de) Gm3-synthase als therapeutisches ziel bei mikrovaskulären komplikationen des diabetes
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
WO2008033562A3 (en) Kinase inhibitor compounds
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
WO2009027346A3 (de) 17beta-hydroxysteroid-dehydrogenase-typ1-inhibitoren zur behandlung hormonabhängiger erkrankungen
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EA200900571A1 (ru) Композиции chk1 ингибиторов
DE602007009095D1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
TW200714283A (en) Method and composition for treating peripheral vascular diseases
ATE554091T1 (de) Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
TW200801008A (en) Protein kinase inhibitors
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
MX2009003658A (es) Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
ATE438404T1 (de) Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
TW200722427A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
MY148644A (en) New pharmaceutical compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties